SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is seeing heightened investor attention amid escalating Middle East tensions, following reports of a drone strike on Saudi Arabia's largest oil refinery and fears over the Strait of Hormuz. The community is actively discussing its potential for a significant short squeeze and a parabolic price run, drawing comparisons to past oil rallies driven by geopolitical events.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp. (BATL) is soaring amidst intense discussions surrounding escalating geopolitical tensions impacting Middle Eastern oil supply and shipping, leading to a surge in crude prices. The low-float oil producer is a focal point for traders anticipating a significant short squeeze due to high short interest and heightened market volatility.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as the critical role of photonics in AI infrastructure draws intensified investor focus, evidenced by recent significant institutional stakes, though community sentiment remains split between high conviction in its optical interconnect technology and impatience for tangible commercialization ahead of the upcoming OFC conference.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing a massive price surge driven by strong earnings and bullish guidance for its 800G transceiver demand from hyperscale data centers, leading to multiple analyst upgrades in the optical networking sector. The community is keenly debating whether the stock's parabolic move reflects genuine long-term potential in AI infrastructure or if it's an overvalued pump-and-dump susceptible to dilution from a recent stock offering.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is surging amidst heightened geopolitical tensions from reported U.S.-Israeli strikes on Iran and subsequent retaliatory attacks, driving community discussion around severe oil supply disruptions if the Strait of Hormuz remains impacted, with many anticipating a significant price surge.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is trending sharply lower after the FDA indicated that Phase I/II data for its Huntington's disease gene therapy, AMT-130, are insufficient for approval, recommending a larger, sham-controlled Phase III trial. The community is actively debating this regulatory setback, questioning the FDA's "moving goalposts" and commitment to accelerating treatments for rare diseases.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending following a solid Q4 earnings beat and a new five-year LNG supply agreement with Trafigura, reinforcing its strong growth trajectory. The community is actively discussing the stock's significant undervaluation compared to its rapidly expanding LNG capacity, emphasizing its strategic advantage in the spot market amid escalating geopolitical tensions in the Strait of Hormuz, which could further drive up global LNG prices and potentially trigger a short squeeze.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Escalating geopolitical tensions in the Middle East, marked by drone strikes on key energy facilities and reports of shipping disruptions in the Strait of Hormuz, are fueling widespread speculation about rapidly rising oil prices. The community is largely bullish on Exxon Mobil, viewing it as a direct beneficiary of the heightened risk premium and anticipating significant upside for the broader energy sector.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending due to a strategic agreement with NVIDIA, which includes a significant investment and commitment for advanced optical components, positioning the company as a key player in the expanding AI data center infrastructure, while community discussions highlight both significant upside and concerns about its valuation.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending following better-than-expected earnings and robust revenue guidance, with its patent defense of Recorlev and a competitor's drug setback from the FDA reinforcing its market position in the growing Cushing's syndrome segment. The community is actively debating management's conservative future guidance but remains optimistic about Recorlev's blockbuster potential and the advancement of XP-8121 into Phase 3.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Smith & Nephew SNATS Q4 Earnings Call Highlights

Smith & Nephew SNATS (NYSE:SNN) executives struck an optimistic tone in the company's fourth-quarter and full-year 2025 results presentation, pointing to a strong finish that landed at the high end...

Smith & Nephew FY25 Results Rise, Lifts Dividend; Sees Growth Ahead

(RTTNews) - Smith & Nephew Plc (SNN, SN.L), a British medical technology company, reported Monday significantly higher profit in fiscal 2025, with increased revenues. Further, the company lifted...

Smith & Nephew plc (LON:SN) Given Average Rating of "Hold" by Brokerages

Shares of Smith & Nephew plc (LON:SN - Get Free Report) have been assigned an average recommendation of "Hold" from the six ratings firms that are currently covering the company, MarketBeat Ratings...

Citigroup Inc. Purchases 150,517 Shares of Smith & Nephew SNATS, Inc. $SNN

Citigroup Inc. boosted its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 44.8% during the 3rd quarter, according to the company in its most recent disclosure with the...

Smith & Nephew SNATS (SNN) Projected to Post Quarterly Earnings on Tuesday

Smith & Nephew SNATS (NYSE:SNN) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 3. (View Earnings Report at...

Optiver Holding B.V. Sells 50,949 Shares of Smith & Nephew SNATS, Inc. $SNN

Optiver Holding B.V. lowered its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 4.4% during the 3rd quarter, according to the company in its most recent disclosure with the...

Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Clark Estates Inc. NY Has $11.79 Million Position in Smith & Nephew SNATS, Inc. $SNN

Clark Estates Inc. NY lowered its position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 51.9% during the third quarter, according to its most recent filing with the SEC. The firm owned...

Smith & Nephew SNATS (NYSE:SNN) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen lowered Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a research note on Saturday...

Smith & Nephew SNATS, Inc. $SNN Stock Holdings Lessened by Heartland Advisors Inc.

Heartland Advisors Inc. cut its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 19.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned...

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Smith & Nephew plc - ADR

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

SNN
Smith & Nephew plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SNN News

SNNSmith & Nephew plc